QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

NRIX

QT73Nurix Therapeutics, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
17.55
+0.43+2.51%
OverviewShort InterestFilings
NRIXQT73Nurix Therapeutics, Inc.·NASDAQ
OverviewShort InterestFilings
17.55+2.51%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-3.16
Insider Own1.67%
Shs Outstand103.41M
Perf Week3.36%
Market Cap1.48BForward P/E-EPS next Y-2.44Insider Trans0.10%Shs Float-Perf Month15.16%
Enterprise Value1.47BPEG0.47EPS next Q-0.73Inst Own-Short Float-Perf Quarter17.63%
Income-232501012.00P/S20.67EPS this Y19.72%Inst Trans-Short Ratio-Perf Half Y-6.85%
Sales71.78MP/B3.92EPS next Y4.01%ROA-46.42%Short Interest-Perf YTD-7.49%
Book/sh4.65P/C-EPS next 5Y-ROE-64.21%52W High22.50 -22.00%Perf Year54.08%
Cash/sh5.23P/FCF-EPS past 3/5Y-ROIC-57.63%52W Low8.20 114.02%Perf 3Y-
Dividend Est.-EV/EBITDA-5.29Sales past 3/5Y29.14% 36.08%Gross Margin-139.43%Volatility5.80% 6.01%Perf 5Y-
Dividend TTM-EV/Sales20.50EPS Y/Y TTM-9.72%Oper. Margin-439.26%ATR (14)1.18Perf 10Y-
Dividend Ex-Date-Quick Ratio6.01Sales Y/Y TTM30.91%Profit Margin-411.37%RSI (14)59.79Recom2.00
Dividend Gr. 3/5Y-Current Ratio6.01EPS Q/Q-17.91%SMA205.17%Beta1.64Target Price33.00
Payout0.00%Debt/Eq0.12Sales Q/Q-66.67%SMA506.09%Rel Volume2.32Prev Close17.12
Employees286LT Debt/Eq0.10EarningsJul 09SMA20016.40%Avg Volume1.83MPrice17.55
IPO DateJul 24, 2020Option/ShortYes / YesEPS/Sales Surpr.-3.95% -57.14%Net Debt/EBITDA0.05Volume4,243,516Change2.51%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-18-26ReiteratedRobert W. Baird$26 → $33
Jun-09-26ReiteratedUBSBuy$35 → $23
Jun-09-26ReiteratedBTIGBuy$30 → $32
Jun-08-26ReiteratedTruist Financial$30 → $32
Jun-08-26ReiteratedJefferiesBuy$41 → $45
Jun-08-26ReiteratedNeedhamBuy$34
Apr-09-26ReiteratedWells FargoOverweight$29 → $28
Jan-29-26ReiteratedStifel Nicolaus$33 → $35
Jan-29-26ReiteratedH.C. Wainwright$31 → $32
Jan-29-26ReiteratedWells FargoOverweight$21 → $29
Latest News
Jun-18-26
Jun-18-2609:00AM
Baird Maintains Outperform on Nurix Therapeutics, Raises Price Target to $33Benzinga
Jun-15-26
Jun-15-2608:16AM
Needham Reiterates Buy on Nurix Therapeutics, Maintains $34 Price TargetBenzinga
Jun-11-26
Jun-11-2609:48AM
Nurix Therapeutics Deal With Roche Is Worth Betting OnSeekingAlpha
07:08AM
Nurix to Present Updated CLL Drug Data at EHA 2026, Says Bexobrutideg Shows Durable Responses in CLL TrialBenzinga
Jun-10-26
Jun-10-2607:31AM
HC Wainwright & Co. Reiterates Buy on Nurix Therapeutics, Maintains $32 Price TargetBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
11/30/2025
FY 2024
11/30/2024
FY 2023
11/30/2023
FY 2022
11/30/2022
FY 2021
11/30/2021
FY 2020
11/30/2020
FY 2019
11/30/2019
FY 2018
11/30/2018
Total Revenue728455
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A17219222
Gross Profit-10065-167
Selling, General and Administrative Excl. Other565346
Research and Development245308222
Other Operating Expense-86-10-222
Operating Income-314-286-213
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)-21-22-20
Net Income Before Taxes-294-264-193
Income Taxes110
Consolidated Net Income-294-264-194
Net Income From Continuing Operations-294-264-194
Net Income-294-264-194
EPS (Recurring)-3.16-3.05-2.88
EPS (Basic, Before Extraordinaries)-3.16-3.05-2.88
EPS (Diluted)-3.16-3.05-2.88
EBITDA-273-245-185
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio26.8118.31—
Gross Margin-138.8977.38-303.64
Operating Margin-436.11-340.48-387.27
Net Margin-408.33-314.29-352.73
Shares Outstanding1108767
Market Capitalization1,9311,538—
Operating Lease Expense
———
Insider Trading Volume
$19.04$17.26$15.49$13.72$11.94● Close Price0.00K180.16K360.31K540.47K720.63KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Ring ChristineChief Legal OfficerJun 02 '26Sale16.608,148135,25313,579Jun 02 12:00 AM
Ring ChristineChief Legal OfficerJun 02 '26Option Exercise1.866,84412,73021,727Jun 02 12:00 AM
van Houte HansChief Financial OfficerMay 05 '26Sale16.6014,055233,31937,592May 05 12:00 AM
Ring ChristineChief Legal OfficerMay 04 '26Sale16.968,148138,21018,305May 04 12:00 AM
Ring ChristineChief Legal OfficerMay 01 '26Sale16.765,39490,40726,453May 01 12:00 AM
Hansen GwennChief Scientific OfficerApr 30 '26Option Exercise0.0017,2160123,613Apr 30 12:00 AM
Hansen GwennChief Scientific OfficerApr 30 '26Sale16.653,21453,498120,399Apr 30 12:00 AM
Ring ChristineChief Legal OfficerApr 30 '26Option Exercise0.0017,216035,061Apr 30 12:00 AM
van Houte HansChief Financial OfficerApr 30 '26Option Exercise0.0017,216054,035Apr 30 12:00 AM
van Houte HansChief Financial OfficerApr 30 '26Sale16.652,38839,74951,647Apr 30 12:00 AM
Ring ChristineChief Legal OfficerApr 30 '26Sale16.653,21453,49831,847Apr 30 12:00 AM
Ring ChristineChief Legal OfficerApr 02 '26Sale15.248,148124,14926,453Apr 02 12:00 AM
Ring ChristineChief Legal OfficerMar 02 '26Sale15.448,148125,79334,601Mar 02 12:00 AM
Ring ChristineChief Legal OfficerFeb 09 '26Sale16.6614,261237,61842,749Feb 09 12:00 AM
Hansen GwennChief Scientific OfficerFeb 03 '26Option Exercise0.8462,66652,640115,005Feb 03 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR